Study to Evaluate the Effect on Nitrogen Retention of Two Different Posology Schemes of PKU GOLIKE PLUS 3-16 and Free AAs in Patients With Phenylketonuria
NCT05229549 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5
Last updated 2023-07-07
Summary
This is an open-label, randomized, 4-way crossover, monocentric, controlled study in patients (3 ≤ years of age ≤ 20 )) with phenylketonuria (PKU).
The primary comparison will be between the test product (PKU GOLIKE PLUS 3-16, a prolonged-release amino-acids (AAs) mixture) and the reference product (an immediate-release free AAs mixture with the same qualitative and quantitative composition of PKU GOLIKE PLUS 3-16). PKU GOLIKE PLUS 3-16 is a food for special medicinal purposes (FSMP) for the dietary management of PKU.
The study will consist of a screening visit (T0), four test days taking place on Sunday (T1-T4), each separated by a washout period (a period of time when a participant is taken off a treatment in order to eliminate its effects) and with the study products being self-administered at home, and a final visit (T5).
Following informed consent and verification of eligibility criteria, 24 patients with PKU will be randomized in a 1:1:1:1 ratio to one of the four randomization sequences ABCD, BDAC, DCBA or CADB.
A, B, C and D will be:
A. One day treatment with 3 self-administrations of GOLIKE PLUS 3-16 (1.2 g/kg total daily dose of AA) B. One day treatment with 2 self-administrations of GOLIKE PLUS 3-16 (1.2 g/kg total daily dose of AA) C. One day treatment with 3 self-administrations of free AAs (1.2 g/kg total daily dose of AA) D. One day treatment with 2 self-administrations of free AAs (1.2 g/kg total daily dose of AA)
GOLIKE PLUS 3-16 and the free AAs mixture will be the only protein substitute allowed on each test day, and no sports activities will be allowed on the test days.
24-hour urines and five blood spots will be collected on each test day. A patient's diary will be used to collect information on patient compliance, 24-hour urines and blood spot collections, diet, daily activities, adverse events and concomitant medications.
Patients completing all four test days will be asked to go to the center for a final visit (T5) taking place within 2 weeks from the last product administration.
Conditions
- Phenylketonurias
Interventions
- OTHER
-
GOLIKE PLUS 3-16
PKU GOLIKE PLUS 3-16 is a food for special medicinal purposes (FSMP) for the dietary management of PKU.
- OTHER
-
Free AAs
It is an immediate-release free AAs mixture with the same qualitative and quantitative composition of PKU GOLIKE PLUS 3-16.
Sponsors & Collaborators
-
APR Applied Pharma Research s.a.
lead OTHER
Principal Investigators
-
Giuseppe Banderali · ASST Santi Paolo e Carlo, Presidio Ospedale San Paolo, Via Antonio di Rudinì 8 - 20142, Milano (Italy)
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 3 Years
- Max Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-05-06
- Primary Completion
- 2022-11-29
- Completion
- 2023-02-07
Countries
- Italy
Study Locations
More Related Trials
-
Gluten Sensitivity in Non-Celiac Patients
NCT01485341 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of PKU UP
NCT05995717 ·Status: COMPLETED ·Phase: NA
-
Tolerance of Cereals for Atopic Children
NCT01029184 ·Status: TERMINATED ·Phase: NA
-
Prevalence of Non Celiac Gluten Sensitivity Among Patients Spontaneously Adherent to Gluten Free Diet
NCT01827566 ·Status: UNKNOWN ·Phase: NA
-
Safety and Efficacy of Varying Methods of ALV003 Administration for the Treatment of Celiac Disease
NCT01255696 ·Status: COMPLETED ·Phase: PHASE2
-
Non Celiac Gluten Sensitivity, DBPCFC in Adolescents
NCT04639921 ·Status: UNKNOWN ·Phase: NA
-
Cross-Over Multicentre Study in Adolescents
NCT00635544 ·Status: COMPLETED ·Phase: NA
-
Risk of Celiac Disease and Age at Gluten Introduction
NCT00639444 ·Status: COMPLETED ·Phase: NA
-
Symptomatic Response to Gluten Challenge in Patients With Suspected Non Celiac Gluten Sensitivity
NCT01864993 ·Status: COMPLETED ·Phase: NA
-
Multicenter Study on the Toxicity of Gluten Traces in the Treatment of Celiac Disease
NCT00250146 ·Status: TERMINATED ·Phase: NA
-
Evaluation of the Express Plus Range
NCT05051657 ·Status: COMPLETED ·Phase: NA
-
In Vivo Effects of the Gluten Friendly Bread in Coeliac Disease
NCT03168490 ·Status: TERMINATED ·Phase: NA
-
Effects of Ancient Grains-based Diet in a Closed Community
NCT03020511 ·Status: COMPLETED ·Phase: NA
-
A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac Disease
NCT03701555 ·Status: COMPLETED ·Phase: PHASE1
-
Carbohydrate Counting and DASH Intervention Among Children With Diabetes and Celiac Disease.
NCT05132725 ·Status: UNKNOWN ·Phase: NA
-
Preservation of Residual Beta Cell Mass and Prevention of Celiac Disease in Children With Recent Onset Type 1 Diabetes
NCT03037190 ·Status: UNKNOWN ·Phase: NA
-
Study of Low-grade Systemic Inflammation in Adult Patients With Phenylketonuria
NCT04879277 ·Status: COMPLETED ·Phase: NA
-
Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Symptomatic CD Patients
NCT04243551 ·Status: TERMINATED ·Phase: PHASE2
-
The Effect of Gluten-free Diet on New Onset Type 1 Diabetes (T1D)
NCT02867436 ·Status: COMPLETED ·Phase: NA
-
Follow up of LEAP Participants and Their Families
NCT03546413 ·Status: COMPLETED
-
Malnutrition In Non-Celiac Wheat Sensitivity Patients
NCT02421796 ·Status: COMPLETED
-
Efficacy of a Gluten-free Diet in Difficult to Manage Nephrotic Syndrome: Utility of Plasma Zonulin Levels as a Predictive Biomarker
NCT03387176 ·Status: COMPLETED
-
Safety and Systemic Exposure Study of BL-7010 in Well-Controlled Celiac Patients.
NCT01990885 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Peanut Oral Induction Tolerance in Peanut's Allergic Teenagers
NCT02046083 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Influence of Persistent Food Allergy on Nutritional Status of Children With Food Allergy
NCT05937061 ·Status: COMPLETED